Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
10035 | 1034 | 38.2 | 81% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1587 | 6631 | FOLATE RECEPTOR//REDUCED FOLATE CARRIER//DIHYDROFOLATE REDUCTASE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | FOLATE RECEPTOR | Author keyword | 164 | 56% | 19% | 201 |
2 | FOLATE BINDING PROTEIN | Author keyword | 35 | 55% | 4% | 44 |
3 | FOLATE RECEPTOR ALPHA | Author keyword | 31 | 64% | 3% | 30 |
4 | CEREBRAL FOLATE DEFICIENCY | Author keyword | 19 | 71% | 1% | 15 |
5 | FARLETUZUMAB | Author keyword | 18 | 83% | 1% | 10 |
6 | FOLATE CONJUGATE | Author keyword | 13 | 80% | 1% | 8 |
7 | EC145 | Author keyword | 9 | 83% | 0% | 5 |
8 | AUTOIMMUNE SEROL | Address | 9 | 59% | 1% | 10 |
9 | KB TUMOR | Author keyword | 8 | 100% | 0% | 5 |
10 | VINTAFOLIDE | Author keyword | 8 | 100% | 0% | 5 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FOLATE RECEPTOR | 164 | 56% | 19% | 201 | Search FOLATE+RECEPTOR | Search FOLATE+RECEPTOR |
2 | FOLATE BINDING PROTEIN | 35 | 55% | 4% | 44 | Search FOLATE+BINDING+PROTEIN | Search FOLATE+BINDING+PROTEIN |
3 | FOLATE RECEPTOR ALPHA | 31 | 64% | 3% | 30 | Search FOLATE+RECEPTOR+ALPHA | Search FOLATE+RECEPTOR+ALPHA |
4 | CEREBRAL FOLATE DEFICIENCY | 19 | 71% | 1% | 15 | Search CEREBRAL+FOLATE+DEFICIENCY | Search CEREBRAL+FOLATE+DEFICIENCY |
5 | FARLETUZUMAB | 18 | 83% | 1% | 10 | Search FARLETUZUMAB | Search FARLETUZUMAB |
6 | FOLATE CONJUGATE | 13 | 80% | 1% | 8 | Search FOLATE+CONJUGATE | Search FOLATE+CONJUGATE |
7 | EC145 | 9 | 83% | 0% | 5 | Search EC145 | Search EC145 |
8 | KB TUMOR | 8 | 100% | 0% | 5 | Search KB+TUMOR | Search KB+TUMOR |
9 | VINTAFOLIDE | 8 | 100% | 0% | 5 | Search VINTAFOLIDE | Search VINTAFOLIDE |
10 | FOLATE RECEPTORS | 8 | 48% | 1% | 12 | Search FOLATE+RECEPTORS | Search FOLATE+RECEPTORS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CULTURED KB CELLS | 61 | 77% | 4% | 41 |
2 | VINCA ALKALOID CONJUGATE | 41 | 85% | 2% | 22 |
3 | EC145 | 30 | 100% | 1% | 12 |
4 | GLYCOSYLPHOSPHATIDYLINOSITOL MODIFICATION | 30 | 84% | 2% | 16 |
5 | KB CELLS | 27 | 27% | 8% | 86 |
6 | HUMAN KB CELLS | 24 | 40% | 5% | 47 |
7 | GA 67 DEFEROXAMINE FOLATE | 15 | 73% | 1% | 11 |
8 | FOLATE RECEPTOR | 11 | 15% | 7% | 71 |
9 | TC 99M EC20 | 11 | 100% | 1% | 6 |
10 | FARLETUZUMAB | 9 | 83% | 0% | 5 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Discovery and development of folic-acid-based receptor targeting for Imaging and therapy of cancer and inflammatory diseases | 2008 | 356 | 60 | 75% |
Engineering Folate-Drug Conjugates to Target Cancer: From Chemistry to Clinic | 2012 | 49 | 41 | 83% |
Folate-targeted therapeutic and imaging agents for cancer | 2009 | 175 | 52 | 69% |
Principles in the design of ligand-targeted cancer therapeutics and imaging agents | 2015 | 7 | 176 | 18% |
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review | 2014 | 8 | 65 | 72% |
Folate-mediated delivery of macromolecular anticancer therapeutic agents | 2002 | 412 | 86 | 64% |
The folate receptor as a rational therapeutic target for personalized cancer treatment | 2014 | 8 | 62 | 68% |
Folate-mediated delivery of macromolecular anticancer therapeutic agents | 2012 | 36 | 87 | 64% |
Folate receptor-mediated drug targeting: From therapeutics to diagnostics | 2005 | 271 | 129 | 64% |
The folate receptor: What does it promise in tissue-targeted therapeutics? | 2007 | 133 | 121 | 66% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | AUTOIMMUNE SEROL | 9 | 59% | 1.0% | 10 |
2 | TRANSLAT MED DIAGNOST | 4 | 75% | 0.3% | 3 |
3 | USZ | 3 | 21% | 1.2% | 12 |
4 | RADIOPHARMACEUT SCI ETH PSI USZ | 2 | 19% | 1.0% | 10 |
5 | UNIT MOL THER IES | 2 | 17% | 0.9% | 9 |
6 | ETH PSI USZ | 1 | 31% | 0.4% | 4 |
7 | CYCLOTRON RADIOPHARMACEUT | 1 | 18% | 0.7% | 7 |
8 | MOL NEUROSURG BIOTECHNOL | 1 | 38% | 0.3% | 3 |
9 | RADIOPHARMACEUT SCI ETH | 1 | 38% | 0.3% | 3 |
10 | AUTISM LIEGE | 1 | 50% | 0.2% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000168222 | REDUCED FOLATE CARRIER//FOLYLPOLYGLUTAMATE SYNTHETASE//HEREDITARY FOLATE MALABSORPTION |
2 | 0.0000102205 | FOOD FOLATE//FOLATE BIOAVAILABILITY//FOLATES |
3 | 0.0000092169 | BOVINE SERUM ALBUMIN NANOPARTICLES//HUMAN SERUM ALBUMIN NANOPARTICLES//COACERVATION METHOD |
4 | 0.0000072260 | CANCER NANOTECHNOLOGY//NANOSCI NANOENGN INITIAT NUSNNI//CHEMOTHERAPEUTIC ENGINEERING |
5 | 0.0000052171 | POLYMERIC MICELLES//POLYMERIC MICELLE//PLURONIC MICELLES |
6 | 0.0000049402 | GEN BIOPHYS//PAMAM DENDRIMERS//MICHIGAN NANOTECHNOL MED BIOL SCI |
7 | 0.0000046918 | LIPOSOME//THERMOSENSITIVE LIPOSOMES//IMMUNOLIPOSOMES |
8 | 0.0000045524 | MULTIMERIC LIGANDS//NDP ALPHA MSH//DISSOCIATION ENHANCED LANTHANIDE FLUOROIMMUNOASSAY |
9 | 0.0000039934 | NEAR INFRARED FLUORESCENCE IMAGING//NEAR INFRARED FLUORESCENCE//FLUORESCENT CHOLANGIOGRAPHY |
10 | 0.0000039376 | TECHNETIUM//TC 99M TRICARBONYL COMPLEX//CYTECTRENE |